UCLA researchers from the Department of Molecular and Medical Pharmacology have developed a dual small-molecule platform for targeted protein degradation in cancer. By combining hypoxia-activated PROTACs with rationally designed molecular glues, this approach addresses key limitations in tumor selectivity.
BACKGROUND: Despite major advances in cancer therapy, a large portion of tumor-driving proteins remain therapeutically elusive with traditional inhibitors—either due to the absence of active sites or the complexity of their interactions. Targeted protein degradation (TPD) offers a compelling alternative by eliminating proteins entirely through the ubiquitin-proteasome system. Two leading approaches in this field include proteolysis-targeting chimeras (PROTACs) and molecular glues. The former are bifunctional molecules that tether a target protein to a degradative enzyme, E3 ligase, while the latter stabilizes native interactions between E3 ligase and the tumor target protein.
While these tools have opened new doors in cancer therapy, significant limitations remain. PROTACs require careful design of two binding elements and often lack tumor selectivity, raising concerns about systemic toxicity. Molecular glues are more compact and drug-like but have historically been discovered by chance, limiting their generalizability. To fully realize the clinical potential of TPD—especially in oncology—there is a clear need for more flexible, selective, and broadly applicable strategies that can overcome these design and delivery challenges.
INNOVATION: UCLA researchers have developed a dual small-molecular platform for targeted protein degradation that combines two complementary approaches: hypoxia-activated PROTACs and rationally designed molecular glues. The hypoxia activated PROTACs remain inert in normal tissue and activate only in low-oxygen tumor environments, improving safety by minimizing off-target effects. In parallel, the molecular glues are compact single agents that trigger degradation by stabilizing interactions between target proteins and degradative E3 ligases—without the complexity of bifunctional design. To overcome the inefficient, traditional trial-and-error limitations of glue discovery, UCLA researchers developed a platform that uses engineered degron-tagged target proteins and high-throughput reporter assays to systematically identify and validate new glue-like compounds. This method enables rational design and screening of glue candidates against specific targets, broadening the potential beyond random screening. Together, these strategies form a unified platform that expands target scope while enhancing selectivity, offering a next-generation solution for safer and more versatile cancer therapeutics.
POTENTIAL APPLICATIONS:
- Targeted degradation of disease-driving proteins beyond the reach of conventional inhibitors
- Tumor-selective therapeutic strategies using conditionally activated degraders
- Systematic discovery and validation of molecular glues across diverse protein classes
- Versatile platform for drug discovery in oncology, with potential expansion to immunology and other indications
ADVANTAGES:
- Combines two complementary degradation mechanism to broaden target scope and improve selectivity
- Enables tumor-specific activation to reduce off-target toxicity
- Simplifies small molecule discovery through a screening platform
- Applicable across multiple therapeutic areas with a strong focus on oncology
DEVELOPMENT-TO-DATE: Both technologies have been validated using in vitro and cell-based degradation assays. The hypoxia-activated PROTACs showed oxygen-dependent activation in biochemical assays and selective degradation in lung and colon cancer cell lines under hypoxic conditions, with no activity observed in normoxia. The molecular glue platform was evaluated using degron-tagged targets and reporter-based assays in HEK293 cells, with activity confirmed by immunoblotting and loss-of-function upon mutation of key binding interfaces. These findings establish proof-of-concept for both tumor-selective activation and rational glue-based degradation.
Keywords: Targeted protein degradation, Hypoxia-Activated Therapeutics, Molecular Glues, Precision Oncology, Conditional Drug Activation, Tumor Selectivity, Small Molecule Therapeutics, Ubiquitin-Proteasome Pathway